The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.
Clinical trial NCT07445308 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07445308
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-12
- Primary completion
- 2028-11-21
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.